BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient managementbroad
promise · Horizon Europe grant · 2023-05-01–2026-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20 is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients brain viability, thereby predicting who will benefit from EVT. Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20 will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| TIME IS BRAIN SL | ES | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.